Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Recordkeeping and Reporting Requirements for Human Food and Cosmetics Manufactured From, Processed With, or Otherwise Containing Material From Cattle, 57937-57939 [2014-22982]
Download as PDF
Federal Register / Vol. 79, No. 187 / Friday, September 26, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0505]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Recordkeeping
and Reporting Requirements for
Human Food and Cosmetics
Manufactured From, Processed With,
or Otherwise Containing Material From
Cattle
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995
(PRA).
DATES: Submit either electronic or
written comments on the collection of
information by October 27, 2014.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0623. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Recordkeeping and Reporting
Requirements for Human Food and
Cosmetics Manufactured From,
Processed With, or Otherwise
Containing Material From Cattle—21
CFR 189.5 and 700.27 (OMB Control
Number 0910–0623)—Revision
FDA’s regulations in §§ 189.5 and
700.27 (21 CFR 189.5 and 700.27) set
forth bovine spongiform
encephalopathy (BSE)-related
restrictions applicable to FDA-regulated
VerDate Sep<11>2014
19:14 Sep 25, 2014
Jkt 232001
human food and cosmetics. The
regulations designate certain materials
from cattle as ‘‘prohibited cattle
materials,’’ including specified risk
materials (SRMs), the small intestine of
cattle not otherwise excluded from
being a prohibited cattle material,
material from nonambulatory disabled
cattle, and mechanically separated (MS)
beef. Sections 189.5(c) and 700.27(c) set
forth the requirements for recordkeeping
and records access for FDA-regulated
human food, including dietary
supplements, and cosmetics
manufactured from, processed with, or
otherwise containing material derived
from cattle. FDA issued these
recordkeeping regulations under the
adulteration provisions in sections
402(a)(2)(C), (a)(3), (a)(4), and (a)(5),
601(c), and 701(a) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
(21 U.S.C. 342(a)(2)(C), (a)(3), (a)(4), and
(a)(5), 361(c), and 371(a)). Under section
701(a) of the FD&C Act, FDA is
authorized to issue regulations for the
FD&C Act’s efficient enforcement. With
regard to records concerning imported
human food and cosmetics, FDA relied
on its authority under sections 701(b)
and 801(a) of the FD&C Act (21 U.S.C.
371(b) and 381(a)). Section 801(a) of the
FD&C Act provides requirements with
regard to imported human food and
cosmetics and provides for refusal of
admission of human food and cosmetics
that appear to be adulterated into the
United States. Section 701(b) of the
FD&C Act authorizes the Secretaries of
Treasury and Health and Human
Services to jointly prescribe regulations
for the efficient enforcement of section
801 of the FD&C Act.
These requirements are necessary
because once materials are separated
from an animal, it may not be possible,
without records, to know the following:
(1) Whether cattle material may contain
SRMs (SRMs include brain, skull, eyes,
trigeminal ganglia, spinal cord, vertebral
column (excluding the vertebrae of the
tail, the transverse processes of the
thoracic and lumbar vertebrae and the
wings of the sacrum), and dorsal root
ganglia from animals less than 30
months old and tonsils and distal ileum
of the small intestine from all animals
of all ages); (2) whether the source
animal for cattle material was inspected
and passed; (3) whether the source
animal for cattle material was
nonambulatory disabled or MS beef; and
(4) whether tallow in a human food or
cosmetics contain less than 0.15 percent
insoluble impurities.
FDA’s regulations in §§ 189.5(c) and
700.27(c) require that manufacturers
and processors of human food and
cosmetics manufactured from,
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
57937
processed with, or otherwise containing
material from cattle establish and
maintain records sufficient to
demonstrate that the human food or
cosmetics are not manufactured from,
processed with, or otherwise containing
prohibited cattle materials. These
records must be retained for 2 years at
the manufacturing or processing
establishment or at a reasonably
accessible location. Maintenance of
electronic records is acceptable, and
electronic records are considered to be
reasonably accessible if they are
accessible from an onsite location.
Records required by these sections and
existing records relevant to compliance
with these sections must be available to
FDA for inspection and copying.
Existing records may be used if they
contain all of the required information
and are retained for the required time
period.
Because FDA does not easily have
access to records maintained at foreign
establishments, FDA regulations in
§§ 189.5(c)(6) and 700.27(c)(6),
respectively, require that when filing for
entry with U.S. Customs and Border
Protection, the importer of record of
human food or cosmetics manufactured
from, processed with, or otherwise
containing cattle material must affirm
that the human food or cosmetics were
manufactured from, processed with, or
otherwise contain cattle material and
must affirm that the human food or
cosmetics were manufactured in
accordance with the applicable
requirements of §§ 189.5 or 700.27. In
addition, if human food or cosmetics are
manufactured from, processed with, or
otherwise containing cattle material, the
importer of record must, if requested,
provide within 5 business days records
sufficient to demonstrate that the
human food or cosmetics are not
manufactured from, processed with, or
otherwise containing prohibited cattle
material.
Upon review of the information
collection requests supporting these
BSE-related regulations, FDA found that
the burdens associated with the
requirements for recordkeeping and
records access found in §§ 189.5(c) and
700.27(c) are in use without current
OMB approval. This collection of
information was previously approved by
OMB under control number 0910–0597.
FDA submitted a timely information
collection request to extend the
approval of 0910–0597, but the request
was denied. To most appropriately
streamline this information collection
and to eliminate redundancy in
information collection requests, FDA
seeks to revise the 0910–0623 collection
to include the reporting and
E:\FR\FM\26SEN1.SGM
26SEN1
57938
Federal Register / Vol. 79, No. 187 / Friday, September 26, 2014 / Notices
recordkeeping elements of 0910–0597.
FDA has included these elements in the
burden estimates and discussion in this
document.
Under FDA’s regulations, FDA may
designate a country from which cattle
materials inspected and passed for
human consumption are not considered
prohibited cattle materials, and their use
does not render human food or
cosmetics adulterated. Sections 189.5(e)
and 700.27(e) provide that a country
seeking to be designated must send a
written request to the Director of the
Center for Food Safety and Applied
Nutrition (CFSAN Director). The
information the country is required to
submit includes information about a
country’s BSE case history, risk factors,
measures to prevent the introduction
and transmission of BSE, and other
information relevant to determining
whether SRMs, the small intestine of
cattle not otherwise excluded from
being a prohibited cattle material,
material from nonambulatory disabled
cattle, or MS beef from the country
seeking designation should be
considered prohibited cattle materials.
FDA uses the information to determine
whether to grant a request for
designation and whether to impose
conditions if a request is granted.
Sections 189.5 and 700.27 further
state that countries designated under
§§ 189.5(e) and 700.27(e) will be subject
to future review by FDA to determine
whether their designations remain
appropriate. As part of this process,
FDA may ask designated countries to
confirm that their BSE situations and
the information submitted by them in
support of their original application has
remained unchanged. FDA may revoke
a country’s designation if FDA
determines that it is no longer
appropriate. Therefore, designated
countries may respond to periodic FDA
requests by submitting information to
confirm that their designations remain
appropriate. FDA uses the information
to ensure the designations remain
appropriate.
Description of Respondents:
Respondents to this information
collection include manufacturers,
processors, and importers of FDAregulated human food, including dietary
supplements, and cosmetics
manufactured from, processed with, or
otherwise containing material derived
from cattle, as well as, with regard to
§§ 189.5(e) and 700.27(e), foreign
governments seeking designation under
those regulations.
In the Federal Register of August 1,
2014 (79 FR 44785), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. Although one comment
was received, it did not respond to the
four collection of information topics
solicited, and therefore, it will not be
discussed in this document.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1
Number of
respondents
21 CFR Section
Number of
responses per
respondent
Total annual
responses
Average burden
per response
Total hours
189.5(c)(6) and 700.27(c)(6) ................................
189.5(e) and 700.27(e); Request for designation
189.5(e) and 700.27(e); Response to request for
review by FDA.
54,825
1
1
1
1
1
54,825
1
1
.033 (2 minutes) ...........
80 ..................................
26 ..................................
1,809
80
26
Total ...............................................................
........................
........................
........................
.......................................
1,915
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
Number of
recordkeepers
21 CFR §§ 189.5(c) and 700.27(c)
Number of
records per
recordkeeper
Total annual
records
Average burden per
recordkeeping
Total hours
Domestic facilities .................................................
Foreign facilities ....................................................
697
916
52
52
36,244
47,632
0.25 (15 minutes) .........
0.25 (15 minutes) .........
9,061
11,908
Total ...............................................................
........................
........................
........................
.......................................
20,969
mstockstill on DSK4VPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Except where otherwise noted, this
estimate is based on FDA’s estimate of
the number of facilities affected by the
final rule entitled ‘‘Recordkeeping
Requirements for Human Food and
Cosmetics Manufactured From,
Processed With, or Otherwise
Containing Material From Cattle,’’
published in the Federal Register of
October 11, 2006 (71 FR 59653 at
59667).
Reporting
FDA’s regulations in §§ 189.5(c)(6)
and 700.27(c)(6) impose a reporting
burden on importers of human food and
VerDate Sep<11>2014
20:25 Sep 25, 2014
Jkt 232001
cosmetics manufactured from,
processed with, or otherwise containing
cattle material. Importers of these
products must affirm that the human
food or cosmetics are not manufactured
from, processed with, or otherwise
containing prohibited cattle materials
and must affirm that the human food or
cosmetics were manufactured in
accordance with the applicable
requirements of §§ 189.5 or 700.27. The
affirmation is made by the importer of
record to FDA through FDA’s
Operational and Administrative System
for Import Support. Affirmation by
importers is expected to take
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
approximately 2 minutes per entry line.
Table 2 of this document shows 54,825
lines of human food and cosmetics
likely to contain cattle materials are
imported annually. The reporting
burden of affirming whether import
entry lines contain cattle-derived
materials is estimated to take 1,809
hours annually (54,825 lines multiplied
by 0.033 (2 minutes) per line).
FDA’s estimate of the reporting
burden for designation under §§ 189.5
and 700.27 is based on its experience
and the average number of requests for
designation received in the past 3 years.
In the last 3 years, FDA has not received
E:\FR\FM\26SEN1.SGM
26SEN1
Federal Register / Vol. 79, No. 187 / Friday, September 26, 2014 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
any requests for designation. Thus, FDA
estimates that one or fewer will be
received annually in the future. Based
on this experience, FDA estimates the
annual number of new requests for
designation will be one. FDA estimates
that preparing the information required
by §§ 189.5 and 700.27 and submitting
it to FDA in the form of a written
request to the CFSAN Director will
require a burden of approximately 80
hours per request. Thus, the burden for
new requests for designation is
estimated to be 80 hours annually, as
shown in table 1, row 1 of this
document.
Under §§ 189.5(e) and 700.27(e),
designated countries are subject to
future review by FDA and may respond
to periodic FDA requests by submitting
information to confirm their
designations remain appropriate. In the
last 3 years, FDA has not requested any
reviews. Thus, FDA estimates that one
or fewer will occur annually in the
future. FDA estimates that the
designated country undergoing a review
in the future will need one-third of the
time it took preparing its request for
designation to respond to FDA’s request
for review, or 26 hours (80 hours
multiplied by 0.33 (2 minutes) = 26.4
hours, rounded to 26). The annual
burden for reviews is estimated to be 26
hours, as shown in table 1, row 2 of this
document. The total annual reporting
burden for this information collection is
estimated to be 1,915 hours.
Recordkeeping
FDA estimates that there are 697
domestic facility relationships and 916
foreign facility relationships consisting
of the following facilities: An input
supplier of cattle-derived materials that
requires records (the upstream facility)
and a purchaser of cattle-derived
materials requiring documentation (this
may be a human food or cosmetics
manufacturer or processor). The
recordkeeping burden of FDA’s
regulations in §§ 189.5(c) and 700.27(c)
is the burden of sending, verifying, and
storing documents regarding shipments
of cattle material that is to be used in
human food and cosmetics.
In this estimate of the recordkeeping
burden, FDA treats these recordkeeping
activities as shared activities between
the upstream and downstream facilities.
It is in the best interests of both facilities
in the relationship to share the burden
necessary to comply with the
regulations; therefore, FDA estimates
the time burden of developing these
records as a joint task between the two
facilities. Thus, FDA estimates that this
recordkeeping burden will be about 15
minutes per week or 13 hours per year,
VerDate Sep<11>2014
19:14 Sep 25, 2014
Jkt 232001
and FDA assumes that the
recordkeeping burden will be shared
between 2 entities (i.e. the ingredient
supplier and the manufacturer of
finished products). Therefore, the total
recordkeeping burden for domestic
facilities is estimated to be 9,061 hours
(13 hours multiplied by 697), and the
total recordkeeping burden for foreign
facilities is estimated to be 11,908 hours
(13 hours multiplied by 916), as shown
in table 1 of this document.
Dated: September 22, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–22982 Filed 9–25–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–D–1242]
Submissions for Early Growth
Response 1 Gene Fluorescence In-Situ
Hybridization Test System for
Specimen Characterization Devices;
Draft Guidance for Industry and Food
and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
availability of the draft guidance
entitled ‘‘Content and Format for
Abbreviated 510(k)s for Early Growth
Response 1 (EGR1) Gene Fluorescence
In-Situ Hybridization (FISH) Test
System for Specimen Characterization
Devices.’’ This draft guidance provides
industry and Agency staff with
recommendations for the suggested
format and content of an abbreviated
510(k) submission for early growth
response 1 (EGR1) gene fluorescence insitu hybridization (FISH) test system for
specimen characterization devices. This
draft guidance is not final nor is it in
effect at this time.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by December 26,
2014.
ADDRESSES: An electronic copy of the
guidance document is available for
download from the Internet. See the
SUPPLEMENTARY INFORMATION section for
Frm 00071
Fmt 4703
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the draft guidance
document entitled ‘‘Content and Format
for Abbreviated 510(k)s for Early
Growth Response 1 (EGR1) Gene
Fluorescence In-Situ Hybridization
(FISH) Test System for Specimen
Characterization Devices’’ to the Office
of the Center Director, Guidance and
Policy Development, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. Identify
comments with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Shyam Kalavar, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5568, Silver Spring,
MD 20993–0002, 301–796–6807.
SUPPLEMENTARY INFORMATION:
I. Background
Notice.
SUMMARY:
PO 00000
57939
Sfmt 4703
This draft guidance document was
developed to provide industry and
Agency staff with recommendations for
the suggested format and content of an
abbreviated 510(k) submission for early
growth response 1 (EGR1) gene
fluorescence in-situ hybridization
(FISH) test system for specimen
characterization devices and
recommendations for addressing certain
labeling issues relevant to the review
process specific to these devices. An
early growth response 1 (EGR1) gene
fluorescence in-situ hybridization
(FISH) test system for specimen
characterization is a device intended to
detect the EGR1 probe target on
chromosome 5q in bone marrow
specimens from patients with acute
myeloid leukemia or myelodysplastic
syndrome. The assay results are
intended to be interpreted only by a
qualified pathologist or cytogeneticist.
These devices do not include automated
systems that directly report results
without review and interpretation by a
qualified pathologist or cytogeneticist.
These devices also do not include any
device intended for use to select patient
therapy, predict patient response to
therapy, or to screen for disease as well
as any device with a claim for a
E:\FR\FM\26SEN1.SGM
26SEN1
Agencies
[Federal Register Volume 79, Number 187 (Friday, September 26, 2014)]
[Notices]
[Pages 57937-57939]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-22982]
[[Page 57937]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0505]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Recordkeeping and
Reporting Requirements for Human Food and Cosmetics Manufactured From,
Processed With, or Otherwise Containing Material From Cattle
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995 (PRA).
DATES: Submit either electronic or written comments on the collection
of information by October 27, 2014.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oirasubmission@omb.eop.gov.
All comments should be identified with the OMB control number 0910-
0623. Also include the FDA docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Recordkeeping and Reporting Requirements for Human Food and Cosmetics
Manufactured From, Processed With, or Otherwise Containing Material
From Cattle--21 CFR 189.5 and 700.27 (OMB Control Number 0910-0623)--
Revision
FDA's regulations in Sec. Sec. 189.5 and 700.27 (21 CFR 189.5 and
700.27) set forth bovine spongiform encephalopathy (BSE)-related
restrictions applicable to FDA-regulated human food and cosmetics. The
regulations designate certain materials from cattle as ``prohibited
cattle materials,'' including specified risk materials (SRMs), the
small intestine of cattle not otherwise excluded from being a
prohibited cattle material, material from nonambulatory disabled
cattle, and mechanically separated (MS) beef. Sections 189.5(c) and
700.27(c) set forth the requirements for recordkeeping and records
access for FDA-regulated human food, including dietary supplements, and
cosmetics manufactured from, processed with, or otherwise containing
material derived from cattle. FDA issued these recordkeeping
regulations under the adulteration provisions in sections 402(a)(2)(C),
(a)(3), (a)(4), and (a)(5), 601(c), and 701(a) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 342(a)(2)(C), (a)(3),
(a)(4), and (a)(5), 361(c), and 371(a)). Under section 701(a) of the
FD&C Act, FDA is authorized to issue regulations for the FD&C Act's
efficient enforcement. With regard to records concerning imported human
food and cosmetics, FDA relied on its authority under sections 701(b)
and 801(a) of the FD&C Act (21 U.S.C. 371(b) and 381(a)). Section
801(a) of the FD&C Act provides requirements with regard to imported
human food and cosmetics and provides for refusal of admission of human
food and cosmetics that appear to be adulterated into the United
States. Section 701(b) of the FD&C Act authorizes the Secretaries of
Treasury and Health and Human Services to jointly prescribe regulations
for the efficient enforcement of section 801 of the FD&C Act.
These requirements are necessary because once materials are
separated from an animal, it may not be possible, without records, to
know the following: (1) Whether cattle material may contain SRMs (SRMs
include brain, skull, eyes, trigeminal ganglia, spinal cord, vertebral
column (excluding the vertebrae of the tail, the transverse processes
of the thoracic and lumbar vertebrae and the wings of the sacrum), and
dorsal root ganglia from animals less than 30 months old and tonsils
and distal ileum of the small intestine from all animals of all ages);
(2) whether the source animal for cattle material was inspected and
passed; (3) whether the source animal for cattle material was
nonambulatory disabled or MS beef; and (4) whether tallow in a human
food or cosmetics contain less than 0.15 percent insoluble impurities.
FDA's regulations in Sec. Sec. 189.5(c) and 700.27(c) require that
manufacturers and processors of human food and cosmetics manufactured
from, processed with, or otherwise containing material from cattle
establish and maintain records sufficient to demonstrate that the human
food or cosmetics are not manufactured from, processed with, or
otherwise containing prohibited cattle materials. These records must be
retained for 2 years at the manufacturing or processing establishment
or at a reasonably accessible location. Maintenance of electronic
records is acceptable, and electronic records are considered to be
reasonably accessible if they are accessible from an onsite location.
Records required by these sections and existing records relevant to
compliance with these sections must be available to FDA for inspection
and copying. Existing records may be used if they contain all of the
required information and are retained for the required time period.
Because FDA does not easily have access to records maintained at
foreign establishments, FDA regulations in Sec. Sec. 189.5(c)(6) and
700.27(c)(6), respectively, require that when filing for entry with
U.S. Customs and Border Protection, the importer of record of human
food or cosmetics manufactured from, processed with, or otherwise
containing cattle material must affirm that the human food or cosmetics
were manufactured from, processed with, or otherwise contain cattle
material and must affirm that the human food or cosmetics were
manufactured in accordance with the applicable requirements of
Sec. Sec. 189.5 or 700.27. In addition, if human food or cosmetics are
manufactured from, processed with, or otherwise containing cattle
material, the importer of record must, if requested, provide within 5
business days records sufficient to demonstrate that the human food or
cosmetics are not manufactured from, processed with, or otherwise
containing prohibited cattle material.
Upon review of the information collection requests supporting these
BSE-related regulations, FDA found that the burdens associated with the
requirements for recordkeeping and records access found in Sec. Sec.
189.5(c) and 700.27(c) are in use without current OMB approval. This
collection of information was previously approved by OMB under control
number 0910-0597. FDA submitted a timely information collection request
to extend the approval of 0910-0597, but the request was denied. To
most appropriately streamline this information collection and to
eliminate redundancy in information collection requests, FDA seeks to
revise the 0910-0623 collection to include the reporting and
[[Page 57938]]
recordkeeping elements of 0910-0597. FDA has included these elements in
the burden estimates and discussion in this document.
Under FDA's regulations, FDA may designate a country from which
cattle materials inspected and passed for human consumption are not
considered prohibited cattle materials, and their use does not render
human food or cosmetics adulterated. Sections 189.5(e) and 700.27(e)
provide that a country seeking to be designated must send a written
request to the Director of the Center for Food Safety and Applied
Nutrition (CFSAN Director). The information the country is required to
submit includes information about a country's BSE case history, risk
factors, measures to prevent the introduction and transmission of BSE,
and other information relevant to determining whether SRMs, the small
intestine of cattle not otherwise excluded from being a prohibited
cattle material, material from nonambulatory disabled cattle, or MS
beef from the country seeking designation should be considered
prohibited cattle materials. FDA uses the information to determine
whether to grant a request for designation and whether to impose
conditions if a request is granted.
Sections 189.5 and 700.27 further state that countries designated
under Sec. Sec. 189.5(e) and 700.27(e) will be subject to future
review by FDA to determine whether their designations remain
appropriate. As part of this process, FDA may ask designated countries
to confirm that their BSE situations and the information submitted by
them in support of their original application has remained unchanged.
FDA may revoke a country's designation if FDA determines that it is no
longer appropriate. Therefore, designated countries may respond to
periodic FDA requests by submitting information to confirm that their
designations remain appropriate. FDA uses the information to ensure the
designations remain appropriate.
Description of Respondents: Respondents to this information
collection include manufacturers, processors, and importers of FDA-
regulated human food, including dietary supplements, and cosmetics
manufactured from, processed with, or otherwise containing material
derived from cattle, as well as, with regard to Sec. Sec. 189.5(e) and
700.27(e), foreign governments seeking designation under those
regulations.
In the Federal Register of August 1, 2014 (79 FR 44785), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. Although one comment was received, it did
not respond to the four collection of information topics solicited, and
therefore, it will not be discussed in this document.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
189.5(c)(6) and 700.27(c)(6).. 54,825 1 54,825 .033 (2 minutes) 1,809
189.5(e) and 700.27(e); 1 1 1 80.............. 80
Request for designation.
189.5(e) and 700.27(e); 1 1 1 26.............. 26
Response to request for
review by FDA.
---------------------------------------------------------------------------------
Total..................... .............. .............. .............. ................ 1,915
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Table 2--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
21 CFR Sec. Sec. 189.5(c) Number of records per Total annual per Total hours
and 700.27(c) recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
Domestic facilities........... 697 52 36,244 0.25 (15 9,061
minutes).
Foreign facilities............ 916 52 47,632 0.25 (15 11,908
minutes).
---------------------------------------------------------------------------------
Total..................... .............. .............. .............. ................ 20,969
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Except where otherwise noted, this estimate is based on FDA's
estimate of the number of facilities affected by the final rule
entitled ``Recordkeeping Requirements for Human Food and Cosmetics
Manufactured From, Processed With, or Otherwise Containing Material
From Cattle,'' published in the Federal Register of October 11, 2006
(71 FR 59653 at 59667).
Reporting
FDA's regulations in Sec. Sec. 189.5(c)(6) and 700.27(c)(6) impose
a reporting burden on importers of human food and cosmetics
manufactured from, processed with, or otherwise containing cattle
material. Importers of these products must affirm that the human food
or cosmetics are not manufactured from, processed with, or otherwise
containing prohibited cattle materials and must affirm that the human
food or cosmetics were manufactured in accordance with the applicable
requirements of Sec. Sec. 189.5 or 700.27. The affirmation is made by
the importer of record to FDA through FDA's Operational and
Administrative System for Import Support. Affirmation by importers is
expected to take approximately 2 minutes per entry line. Table 2 of
this document shows 54,825 lines of human food and cosmetics likely to
contain cattle materials are imported annually. The reporting burden of
affirming whether import entry lines contain cattle-derived materials
is estimated to take 1,809 hours annually (54,825 lines multiplied by
0.033 (2 minutes) per line).
FDA's estimate of the reporting burden for designation under
Sec. Sec. 189.5 and 700.27 is based on its experience and the average
number of requests for designation received in the past 3 years. In the
last 3 years, FDA has not received
[[Page 57939]]
any requests for designation. Thus, FDA estimates that one or fewer
will be received annually in the future. Based on this experience, FDA
estimates the annual number of new requests for designation will be
one. FDA estimates that preparing the information required by
Sec. Sec. 189.5 and 700.27 and submitting it to FDA in the form of a
written request to the CFSAN Director will require a burden of
approximately 80 hours per request. Thus, the burden for new requests
for designation is estimated to be 80 hours annually, as shown in table
1, row 1 of this document.
Under Sec. Sec. 189.5(e) and 700.27(e), designated countries are
subject to future review by FDA and may respond to periodic FDA
requests by submitting information to confirm their designations remain
appropriate. In the last 3 years, FDA has not requested any reviews.
Thus, FDA estimates that one or fewer will occur annually in the
future. FDA estimates that the designated country undergoing a review
in the future will need one-third of the time it took preparing its
request for designation to respond to FDA's request for review, or 26
hours (80 hours multiplied by 0.33 (2 minutes) = 26.4 hours, rounded to
26). The annual burden for reviews is estimated to be 26 hours, as
shown in table 1, row 2 of this document. The total annual reporting
burden for this information collection is estimated to be 1,915 hours.
Recordkeeping
FDA estimates that there are 697 domestic facility relationships
and 916 foreign facility relationships consisting of the following
facilities: An input supplier of cattle-derived materials that requires
records (the upstream facility) and a purchaser of cattle-derived
materials requiring documentation (this may be a human food or
cosmetics manufacturer or processor). The recordkeeping burden of FDA's
regulations in Sec. Sec. 189.5(c) and 700.27(c) is the burden of
sending, verifying, and storing documents regarding shipments of cattle
material that is to be used in human food and cosmetics.
In this estimate of the recordkeeping burden, FDA treats these
recordkeeping activities as shared activities between the upstream and
downstream facilities. It is in the best interests of both facilities
in the relationship to share the burden necessary to comply with the
regulations; therefore, FDA estimates the time burden of developing
these records as a joint task between the two facilities. Thus, FDA
estimates that this recordkeeping burden will be about 15 minutes per
week or 13 hours per year, and FDA assumes that the recordkeeping
burden will be shared between 2 entities (i.e. the ingredient supplier
and the manufacturer of finished products). Therefore, the total
recordkeeping burden for domestic facilities is estimated to be 9,061
hours (13 hours multiplied by 697), and the total recordkeeping burden
for foreign facilities is estimated to be 11,908 hours (13 hours
multiplied by 916), as shown in table 1 of this document.
Dated: September 22, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-22982 Filed 9-25-14; 8:45 am]
BILLING CODE 4164-01-P